Onkológia 3/2020
Ixazomib, lenalidomide, dexamethasone in the treatment of patients with relapsed and refractory multiple myeloma
Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. This review provides an overview of the pharmacology and dosing of ixazomib, the efficacy and safety data, and highlights the novel combinations with lenalidomide and dexamethasone.
Keywords: proteasome inhibitor, ixazomib, multiple myeloma
